323105 VU Innovation & Leadership in Preclinical Drug Development - MPS5 (2022S)
Prüfungsimmanente Lehrveranstaltung
Labels
Details
Sprache: Englisch
Lehrende
Termine
Tuesday 01 March 17.00 – 19:00 Uhr s.t.
Thursday 03 March 17.00 – 19:00 Uhr s.t.
Tuesday 08 March 17.00 – 19:00 Uhr s.t.
Thursday 10 March 17.00 – 19:00 Uhr s.t.
Tuesday 15 March 17.00 – 19:00 Uhr s.t.
Thursday 17 March 17.00 – 19:00 Uhr s.t.
Tuesday 22 March 17.00 – 19:00 Uhr s.t.
Thursday 24 March 17.00 – 19:00 Uhr s.t.
Tuesday 29 March 17.00 – 19:00 Uhr s.t.
Tuesday 05 April 17.00 – 19:00 Uhr s.t.
Thursday 07 April 17.00 – 19:00 Uhr s.t.
Final Evaluation: Tuesday 03 May 17.00 – 19.00 Uhr s.t.
Information
Ziele, Inhalte und Methode der Lehrveranstaltung
Art der Leistungskontrolle und erlaubte Hilfsmittel
1. Attendance & Participation: participants are expected to attend all course sessions and actively participate in the course.
2. Three team oral presentations and exercises to be handed in as outlined during the course.
3. Participants will be assessed individually on attendance, application of concepts learned in class, relevant participation in discussions, active and meaningful contribution to team assignments and exercises.
2. Three team oral presentations and exercises to be handed in as outlined during the course.
3. Participants will be assessed individually on attendance, application of concepts learned in class, relevant participation in discussions, active and meaningful contribution to team assignments and exercises.
Mindestanforderungen und Beurteilungsmaßstab
-Class attendance.
- Active participation in class and with team.
- Deliver assignments as outlined in class.
- Three (3) oral presentations (team effort).
Final Presentation (3rd)- Final evaluation. Presentation of pitch and early stage solution design concept (team effort).
- Active participation in class and with team.
- Deliver assignments as outlined in class.
- Three (3) oral presentations (team effort).
Final Presentation (3rd)- Final evaluation. Presentation of pitch and early stage solution design concept (team effort).
Prüfungsstoff
Required Final Assignment - Oral presentation with a developed story line (Pitch), and a primitive prototype design (early stage mock-up of the design concept) [team effort]. Presentation to be submitted by email (PPT, KEY or OpenOffice formats) before it is given orally. Content and requirements to be discussed in class.
Literatur
Recommended Reading (optional):
1. Ross, Alec. The Industries of the Future. Simon & Schuster, 2016.
2. Kelley, Tom. The Art of Innovation. New York: Doubleday, 2005.
3. Gallo, Carmine. The Innovation Secrets of Steve Jobs. New York: McGraw-Hill, 2011, 31.
4. Vise, David & Mark Malseed. The Google Story. New York: Dela- corte Press, 2005, 256.
5. John Battelle. The Search: How Google and Its Rivals Rewrote the Rules of Business and Transformed Our Culture. New York: Penguin Group, 2005, 141.
6. Dyer, Jeff, Hal Gregersen & Clayton M. Christiansen. The Innovator’s DNA. Boston, MA: Harvard Business School Press, 2011.
7. Christensen, Clayton M. & Michael Raynor. Innovator’s Solution. Boston, MA: Harvard Business School Press, 2003.
8. Christensen, Clayton M. The Innovator’s Dilemma: When New Technologies Cause Great Firms to Fail. Boston, MA, Harvard Business School Press, 1997.
9. Christensen, Clayton M. Meeting the Challenge of Disruptive Change. Harvard Bus. School Press, 1997.
10. “The Life and Work of Dr. Paul." https://www.janssen.com/belgium/life-and-work-dr-paul
11. European countries on their journey towards national eHealth infrastructures. January 2011. DOI:10.2759/47528. Publisher: Office des publications officielles des Communities européennes. ISBN: 978-92-79-19766-6. http://ehealth-strategies.eu/database/documents/Austria_CountryBrief_eHStrategies.pdf
12. Abou-Gharbia, M. & Childers, W.E. Discovery of Innovative Therapeutics: Today's Realities and Tomorrow's Vision. 1. Criticisms Faced by the Pharmaceutical Industry. J. Med. Chem. (2016):56, 5659.
13. Brown, Tim. Design Thinking. Harvard Business Review (2008), 84.
14. Mottl, J. Why today’s smartphones may be the only tech patients need. 13 December 2014. Available from: h p://www. ercemobilehealthcare.com/story/why-todays-smartphones- may-be-only-wearables-pa ents-need/2014-12-13.
15.Elvidge, S. Footfalls & Heartbeats: Smart knitted textiles for quanti ed self and patient monitoring Start-Up, 17 December 2013. https://www.innovationintextiles.com/footfalls-heartbeats-launches-crowdfunding-campaign-to-produce-smart-knitted-fabrics/
16. Szcerba, R.J. No Donor Required: 5 Body Parts You Can Make With 3-D Printers. Forbes, 17June 2016. https://www.forbes.com/sites/robertszczerba/2015/06/17/no-donor-required-5-body-parts-you-can-make-with-3-d-printers-2/#
17. Szczerba, R.J. Why Mobile Health Technologies Haven’t Taken Off (Yet). Forbes, 16 July 2014. https://www.forbes.com/sites/robertszczerba/2014/07/16/why-mobile-health-technologies-havent-taken-off-yet/#2bfcf73076ed
1. Ross, Alec. The Industries of the Future. Simon & Schuster, 2016.
2. Kelley, Tom. The Art of Innovation. New York: Doubleday, 2005.
3. Gallo, Carmine. The Innovation Secrets of Steve Jobs. New York: McGraw-Hill, 2011, 31.
4. Vise, David & Mark Malseed. The Google Story. New York: Dela- corte Press, 2005, 256.
5. John Battelle. The Search: How Google and Its Rivals Rewrote the Rules of Business and Transformed Our Culture. New York: Penguin Group, 2005, 141.
6. Dyer, Jeff, Hal Gregersen & Clayton M. Christiansen. The Innovator’s DNA. Boston, MA: Harvard Business School Press, 2011.
7. Christensen, Clayton M. & Michael Raynor. Innovator’s Solution. Boston, MA: Harvard Business School Press, 2003.
8. Christensen, Clayton M. The Innovator’s Dilemma: When New Technologies Cause Great Firms to Fail. Boston, MA, Harvard Business School Press, 1997.
9. Christensen, Clayton M. Meeting the Challenge of Disruptive Change. Harvard Bus. School Press, 1997.
10. “The Life and Work of Dr. Paul." https://www.janssen.com/belgium/life-and-work-dr-paul
11. European countries on their journey towards national eHealth infrastructures. January 2011. DOI:10.2759/47528. Publisher: Office des publications officielles des Communities européennes. ISBN: 978-92-79-19766-6. http://ehealth-strategies.eu/database/documents/Austria_CountryBrief_eHStrategies.pdf
12. Abou-Gharbia, M. & Childers, W.E. Discovery of Innovative Therapeutics: Today's Realities and Tomorrow's Vision. 1. Criticisms Faced by the Pharmaceutical Industry. J. Med. Chem. (2016):56, 5659.
13. Brown, Tim. Design Thinking. Harvard Business Review (2008), 84.
14. Mottl, J. Why today’s smartphones may be the only tech patients need. 13 December 2014. Available from: h p://www. ercemobilehealthcare.com/story/why-todays-smartphones- may-be-only-wearables-pa ents-need/2014-12-13.
15.Elvidge, S. Footfalls & Heartbeats: Smart knitted textiles for quanti ed self and patient monitoring Start-Up, 17 December 2013. https://www.innovationintextiles.com/footfalls-heartbeats-launches-crowdfunding-campaign-to-produce-smart-knitted-fabrics/
16. Szcerba, R.J. No Donor Required: 5 Body Parts You Can Make With 3-D Printers. Forbes, 17June 2016. https://www.forbes.com/sites/robertszczerba/2015/06/17/no-donor-required-5-body-parts-you-can-make-with-3-d-printers-2/#
17. Szczerba, R.J. Why Mobile Health Technologies Haven’t Taken Off (Yet). Forbes, 16 July 2014. https://www.forbes.com/sites/robertszczerba/2014/07/16/why-mobile-health-technologies-havent-taken-off-yet/#2bfcf73076ed
Zuordnung im Vorlesungsverzeichnis
Letzte Änderung: Di 18.01.2022 08:49
This course is in English and fulfills 2 ECTS.
An experiential learning method allows students to apply concepts covered in class to real situations.
- Laptops, tablets, phones or other devices are allowed and encouraged in this class. These tools will enable you to search the internet and gather information for your projects and class discussion.